Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an increase in intestinal permeability seem to be key in the development and progression of NAFLD. Therefore, the manipulation of microbiota seems to provide a promising therapeutic strategy. One way to do so is through faecal microbiota transplantation (FMT). Here, we summarize the key aspects of FMT, detail its current indications and highlight the most recent advances in NAFLD.

Automated summary

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) currently. Lifestyle change is the only available therapeutic recommendation, but adherence to this approach is often challenging. Manipulation of the microbiota and improving intestinal permeability may offer promising therapeutic strategies for NAFLD. Faecal microbiota transplantation (FMT) is a potential method to achieve this. In this review, we summarize key aspects of FMT, discuss its current indications, and highlight recent advances in NAFLD.